AVM Biotechnology is set to study its small molecule, AVM0703, for reversing Type 1 diabetes (T1D) with the receipt of a Phase II Small Business Innovation Research (SBIR) award of $1.6m from the National Institute of Diabetes and Digestive Kidney Disease (NIDDK).

The latest grant will permit the company to carry out further research into using AVM0703 as a single agent and as a combination treatment for reversing recent onset and established T1D.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

This Phase II project will advance the preclinical research, to speed up data acquisition that will facilitate in seeking an investigational new drug application (IND).

Subsequently, this move will aid in launching clinical trials of the therapy. 

The award will be provided over a period of two years and the second-year payment is contingent to fund availability and the study’s satisfactory advancement.

See Also:

The initial goal of the programme is to carry out a preclinical dose-finding and mechanism of action (MOA) study in three settings including pre-diabetic, new-onset and established diabetes.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

These findings will be leveraged to establish the targeted dose to be used in a pivotal efficacy study to reverse new-onset and established diabetes. 

AVM0703 is expected to complement other immunotherapies in individuals who do not show remission, permitting a broader patient population to attain insulin independence.

The latest NIDDK grant comes after the company obtained a Phase I grant in 2019 to study targeted lympho-ablation as a substitute for treating T1D. 

According to data from this preclinical research programme, in 55% of treated mice, AVM0703 was demonstrated to substantially delay T1D onset by 20-31 weeks.

Furthermore, the treatment averted the onset of diabetes in the other 45% of mice. 

T1D is an autoimmune disease that causes damage to the insulin-making beta cells in the pancreas.